Medtronic Talent Thoracic Stent Shows Aptitude In Limiting Mortality
This article was originally published in The Gray Sheet
Executive Summary
Results of Medtronic's VALOR trial show that 30-day all-cause mortality with the firm's recently launched Talent endovascular thoracic stent graft was 2% versus 8% for patients undergoing open surgery to repair thoracic aortic aneurysms